drugset
drugset / Trial / NCT04505839

First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

NCT04505839 ↗

Phase 1 Completed 32 enrolled ST Pharm Co., Ltd. KCRN Research, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.

Timeline

Start
2020-07-30
Primary completion
2023-03-07
Completion
2023-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject STP1002 Unknown — Oral

Indications

neoplasm